Table 1 Patient and treatment characteristics for all patients (left panel) recurrent patients (middle-left panel) and the ARO-analogue subgroup (middle-right panel) and patients with HPV-p16 positive oropharyngeal carcinoma (right panel)
Factors | All patients n = 302 | Recurrent n = 24 | ARO-analogue n = 138 | HPVOPC n = 60 | ||||
|---|---|---|---|---|---|---|---|---|
Number | Percent | Number | Percent | Number | Percent | Number | Percent | |
Primary Tumor | ||||||||
Oropharynx | 149 | 49.3 | 4 | 16.7 | 76 | 55.1 | 60 | 100.0 |
Oral cavity | 63 | 20.9 | 6 | 25.0 | 20 | 14.5 | 0 | 0.0 |
Hypopharynx | 39 | 12.9 | 3 | 12.5 | 24 | 17.4 | 0 | 0.0 |
Larynx | 51 | 16.9 | 11 | 45.8 | 18 | 13.0 | 0 | 0.0 |
Sex | ||||||||
male | 226 | 74.8 | 18 | 75.0 | 108 | 78.3 | 40 | 66.7 |
female | 76 | 25.2 | 6 | 25.0 | 30 | 21.7 | 20 | 33.3 |
Age | ||||||||
< 45 | 11 | 3.6 | 0 | 0 | 5 | 3.6 | 5 | 8.3 |
45–54 | 66 | 21.9 | 5 | 20.8 | 36 | 26.1 | 6 | 10.0 |
55–64 | 114 | 37.7 | 7 | 29.2 | 63 | 45.7 | 24 | 40.0 |
65–74 | 88 | 29.1 | 9 | 37.5 | 32 | 23.2 | 19 | 31.7 |
> 75 | 23 | 7.6 | 3 | 12.5 | 2 | 1.4 | 6 | 10.0 |
UICC Stage 7th edition (a 8th edition for HPVOPC) | ||||||||
I | 7 | 2.3 | 4 | 16.7 | 0 | 0.0 | 1 (42a) | 1.7 (70.0a) |
II | 30 | 9.9 | 0 | 0 | 5 | 3.6 | 4 (16a) | 6.7 (26.7a) |
III | 78 | 25.8 | 7 | 29.2 | 23 | 16.7 | 11 (2a) | 18.3 (3.3a) |
IV | 187 | 61.9 | 13 | 54.2 | 110 | 79.7 | 44 (0a) | 73.3 (0.0a) |
Diagnosis class | ||||||||
First diagnosis | 272 | 90.1 | 0 | 0 | 125 | 90.6 | 59 | 98.3 |
Recurrence | 24 | 7.9 | 24 | 100.0 | 11 | 8.0 | 1 | 1.7 |
Second primary | 6 | 2.0 | 0 | 0 | 2 | 1.4 | 0 | 0 |
T-Stage | ||||||||
T0 | 2 | 0.7 | 2 | 8.3 | 2 | 1.4 | 0 | 0.0 |
T1 | 56 | 18.5 | 6 | 25.0 | 28 | 20.3 | 12 | 20.0 |
T2 | 121 | 40.1 | 1 | 4.2 | 44 | 31.9 | 36 | 60.0 |
T3 | 74 | 24.5 | 6 | 25.0 | 40 | 29.0 | 10 | 16.7 |
T4 | 49 | 16.2 | 9 | 37.5 | 24 | 17.4 | 2 | 3.3 |
N-Stage | ||||||||
N0 | 89 | 29.5 | 12 | 50.0 | 19 | 13.8 | 8 | 13.3 |
N1 | 58 | 19.2 | 6 | 25.0 | 23 | 16.7 | 9 | 15 |
N2a | 23 | 7.6 | 0 | 0 | 15 | 10.9 | 10 | 16.7 |
N2b | 85 | 28.1 | 5 | 20.8 | 47 | 34.1 | 25 | 41.7 |
N2c | 42 | 13.9 | 1 | 4.2 | 30 | 21.7 | 8 | 13.3 |
N3 | 5 | 1.7 | 0 | 0 | 4 | 2.9 | 0 | 0 |
M-Stage | ||||||||
M0 | 302 | 100 | 24 | 100 | 138 | 100 | 60 | 100 |
M1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Resection status (R-Status) | ||||||||
R0 | 150 | 51.0 | 7 | 33.3 | 47 | 35.1 | 26 | 44.1 |
R0-Close margin | 75 | 25.5 | 7 | 33.3 | 43 | 32.1 | 12 | 20.3 |
R1 | 69 | 23.5 | 7 | 33.3 | 44 | 32.8 | 21 | 35.6 |
N/A | 8 | 3 | 4 | 1 | ||||
Extracapsular extension (ECE) | ||||||||
no (N0) | 89 | 29.8 | 12 | 52.5 | 19 | 13.9 | 8 | 13.3 |
no (N+) | 132 | 44.1 | 6 | 26.1 | 59 | 43.1 | 34 | 56.7 |
yes | 78 | 26.1 | 5 | 21.7 | 59 | 43.1 | 18 | 30.0 |
N/A | 3 | 1 | 1 | 0 | ||||
Perineural invasion (PNI) | ||||||||
no (Pn0) | 198 | 83.5 | 8 | 88.9 | 86 | 82.7 | 41 | 87.2 |
yes (Pn1) | 39 | 16.5 | 1 | 11.1 | 18 | 17.3 | 6 | 12.8 |
N/A | 65 | 15 | 34 | 13 | ||||
Lymphatic Invasion (LI) | ||||||||
no (L0) | 201 | 73.4 | 11 | 78.6 | 82 | 66.1 | 40 | 69.0 |
yes (L1) | 73 | 26.6 | 3 | 21.4 | 42 | 33.9 | 18 | 31.0 |
N/A | 28 | 10 | 14 | 2 | ||||
Vascular Invasion (VI) | ||||||||
no (V0) | 266 | 97.1 | 12 | 100 | 119 | 96.0 | 55 | 96.5 |
yes (V1) | 8 | 2.9 | 0 | 0 | 5 | 4.0 | 2 | 3.5 |
N/A | 28 | 12 | 14 | 3 | ||||
Grading | ||||||||
G1 | 9 | 3.0 | 2 | 8.7 | 2 | 1.5 | 0 | 0.0 |
G2 | 119 | 39.5 | 11 | 47.8 | 45 | 32.8 | 11 | 18.3 |
G3 | 173 | 57.5 | 10 | 43.4 | 90 | 65.7 | 49 | 81.7 |
N/A | 1 | 1 | 1 | 0 | ||||
HPV p16 | ||||||||
negative | 159 | 68.2 | 11 | 73.3 | 66 | 61.7 | 0 | 0.0 |
positive | 74 | 31.8 | 4 | 26.7 | 41 | 38.8 | 60 | 100.0 |
HPVOPC | 60 | 20.5 | 1 | 6.7 | 36 | 25.2 | 60 | 100.0 |
N/A | 69 | 9 | 31 | 0 | ||||
RT dose in tumor bed | ||||||||
< 60 Gy (not completed) | 9 | 3 | 2 | 8.3 | 4 | 2.9 | 2 | 3.3 |
60–63.9 Gy | 8 | 2.6 | 0 | 0 | 6 | 4.3 | 3 | 5.0 |
64 Gy | 263 | 87.1 | 21 | 87.5 | 120 | 87 | 52 | 86.7 |
66 Gy | 22 | 7.3 | 1 | 4.2 | 8 | 4.8 | 3 | 5.0 |
RT technique | ||||||||
3d-conformal | 245 | 81.1 | 21 | 87.5 | 116 | 84.1 | 41 | 68.3 |
IMRT | 57 | 18.9 | 3 | 12.5 | 22 | 15.9 | 19 | 31.7 |
Concomitant chemotherapy | ||||||||
no Chx | 126 | 41.7 | 10 | 41.7 | 0 | 0.0 | 16 | 26.7 |
despite indicated | 43 | 14.2 | 5 | 20.8 | 0 | 0.0 | 4 | 6.7 |
Med. | 20 | 4 | 0 | 0.0 | 2 | 3.3 | ||
Pat. Refusal | 23 | 1 | 0 | 0.0 | 2 | 3.3 | ||
Any Chemo | 176 | 58.3 | 14 | 58.3 | 138 | 100.0 | 44 | 73.3 |
CDDP/5-FU | 138 | 78.4 | 11 | 45.8 | 138 | 100.0 | 36 | 81.8 |
CDDP mono | 9 | 5.1 | 1 | 4.2 | 0 | 0.0 | 3 | 6.8 |
Cetuximab | 1 | 0.6 | 0 | 0 | 0 | 0.0 | 0 | 0.0 |
5-FU/MMC | 8 | 4.5 | 1 | 4.2 | 0 | 0.0 | 3 | 6.8 |
MMC | 20 | 11.4 | 1 | 4.2 | 0 | 0.0 | 2 | 4.5 |
Chemo completed | 147 | 83.5 | 14 | 58.3 | 120 | 87.0 | 36 | 81.8 |
Chemo stopped | 29 | 16.5 | 0 | 18 | 13.0 | 8 | 18.1 | |
patient refused | 8 | 0 | 6 | 2 | ||||
Worsening condition | 7 | 0 | 3 | 3 | ||||
cytopenia | 9 | 0 | 4 | 1 | ||||
reaction to chemo | 5 | 0 | 5 | 2 | ||||
Death causes | ||||||||
Tumor-related | 42 | 3 | 21 | 1 | ||||
comorbidities | 40 | 3 | 13 | 6 | ||||
therapy-associated | 2 | 0 | 0 | 1 | ||||
Second primary | 8 | 0 | 4 | 0 | ||||
other | 5 | 0 | 3 | 0 | ||||